Domestic pharma sale declines 6.3percent for second consecutive month in row

Mumbai, June 25, 2022:

The domestic pharma retail market has witnessed 6.3 per cent decline in May as compared to the same month last year. This is the second consecutive month-on-month decline indicating a slowdown in the overall industry growth. The pharma market went down 9 per cent in April this year.

Corresponding to degrowth reported successively for the second month, the domestic pharmaceutical moving annual turnover (MAT) growth also declined to 8.1 per cent in May as compared to 12.3 per cent in April. Both acute and chronic therapies edged down 2.6 per cent and 2 per cent respectively leading to 2.4 per cent decline in overall sales in May as against April, according to the latest figures by market research firm IQVIA.

As per market annual turnover for May 2022, the Indian pharma market was valued at Rs. 182,792 crore.

Except May 2018 and May 2020 witnessing 1.5 per cent and 1 per cent increase in overall sales respectively, May overall sales have always been lower than the previous April month sale. However, May 2021 saw the steepest decline in sales. The overall sale in May 2021 reported a 5.6 per cent decrease as compared to April 2021, stated IQVIA.

Acute drug segment reported a 10.7 per cent fall in May this year as compared to 60.8 per cent growth in acute therapies in the same month last year. While the chronic drug segment witnessed 1.9 per cent growth in May this year as against 31.9 per cent increase in chronic therapies in the same month previous year.
 
The domestic pharma market’s overall sales moved down 6.3 per cent in May this year as against 49.3 per cent growth in overall sales in the same month a year ago. May 2021 exceptional high growth over May 2020 could be one of the main reasons for the domestic pharma market degrowth for May 2022 as compared to May 2021, IQVIA stated.
 
Moving annual turnover for chronic segment in May has grown slightly faster at the rate of 8.5 per cent as compared to acute segment, which has grown by 7.9 per cent.  Highest contribution to growth for the chronic segment came from cardiac contributing 21.8 per cent followed by neuro/CNS at 19.1 per cent and respiratory at 16.5 per cent to the segment growth.

Anti-infective, gastrointestinal, vitamins/minerals/nutrients are the top 3 therapies of acute segment for MAT May.

In the acute segment, Indian companies have grown by 8.2 per cent while MNC have grown by 6.1 per cent in May. In the chronic segment, there is a big gap emerging in the performance of Indian companies and MNC from 2020. Indian companies have grown by 10 per cent while MNC have grown by 2.3 per cent in May 2022. At overall level, Indian companies grew by 8.9 per cent while MNC grew by 4.6 per cent this month.

On the moving annual turnover basis, La Renon, J.B Pharma, Corona Remedies, Ajanta Pharma and IPCA Labs were the top 5 fastest growing among the top 40 companies in the domestic pharma retail market in May. Bharat Serum gained 14 ranks to reach 42nd position. 72 brands of TTK Healthcare were transferred to Bharat Serum in May 2022. Blue Cross gained 2 ranks to reach 31st position. DRL, Aristo, JB Pharma, Eris, Indoco, La Renon, Medley, Win Medicare all gained 1 rank each to reach 10th, 11th, 23rd, 24th, 29th, 30th, 34th and 40th position, respectively.
 
On a MAT basis, Ryzodeg, Calpol, Udiliv, Dolo and Pan were the top 5 fastest growing brands in May among the top 40 brands in the domestic pharma market.
 
The Opthal/Otological segment grew by 38.4 per cent in May this year as compared to April. Refresh Tears, Combigan, Systane-Ultra, Genteal and Vigamox were the top 5 brands in this segment for the same period. Urology segment grew by 26.6 per cent in May as compared to April. Manforce, Urimax-D, Urimax, Megalis and Cystone were the top 5 brands in this segment for the same period.
 
Total 146 new products were launched in May 2022. New brands launched in the last 12 month have clocked a sale of Rs. 1139.5 crore as compared to Rs. 1,262.6 crore reported last month. New products contributed 8.3 per cent to domestic pharma market growth in May. By value, it contributed 0.6 per cent to the domestic market. 62 per cent of new products by value were launched in the acute segment while 38 per cent by value were launched in the chronic segment in the last 12 months ending May. Dydrogest (Zydus), Posaforce (Mankind), Zuviston (Emcure) Molnatris (Mylan), and Divatron (Jagsonpal) were top selling new brands launched in the last 12 months in the acute segment. Toujeo (Sanofi), Rybelsus (Abbott), Lonocart (Bharat Serum), SGLTR-V (Mankind), Remo-MV (Glenmark) were top selling new brands launched in the last 12 months in the chronic segment. Pharmabiz